Abstract Details
Edward C. Cooper, MD, PhD
(Baylor College of Medicine)
PRESENTER |
Dr. Cooper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Xenon Pharmaceuticals. Dr. Cooper has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Knopp Biosciences. The institution of Dr. Cooper has received research support from Xenon Pharmaceuticals. The institution of Dr. Cooper has received research support from Knopp Biosciences. The institution of Dr. Cooper has received research support from The Jack Pribaz Foundation. The institution of Dr. Cooper has received research support from FamilieSCN2A. The institution of Dr. Cooper has received research support from KCNQ2 Cure Alliance. |
John J. Millichap, MD, FAAN (Northwestern University Feinberg School of Medicine) | Dr. Millichap has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Dr. Millichap has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis. Dr. Millichap has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Millichap has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Praxis. Dr. Millichap has received publishing royalties from a publication relating to health care. |
Tammy Tsuchida, MD, PhD (Children's National Hospital) | The institution of Dr. Tsuchida has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon Pharmaceuticals Inc. The institution of Dr. Tsuchida has received research support from Xenon Pharmaceuticals Inc. |
No disclosure on file | |
No disclosure on file |